IL199680A0 - Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof - Google Patents

Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof

Info

Publication number
IL199680A0
IL199680A0 IL199680A IL19968009A IL199680A0 IL 199680 A0 IL199680 A0 IL 199680A0 IL 199680 A IL199680 A IL 199680A IL 19968009 A IL19968009 A IL 19968009A IL 199680 A0 IL199680 A0 IL 199680A0
Authority
IL
Israel
Prior art keywords
same
compositions
processes
producing
ths
Prior art date
Application number
IL199680A
Other languages
English (en)
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700124A external-priority patent/GB0700124D0/en
Priority claimed from GB0708740A external-priority patent/GB0708740D0/en
Priority claimed from GB0719762A external-priority patent/GB0719762D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of IL199680A0 publication Critical patent/IL199680A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL199680A 2007-01-04 2009-07-02 Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof IL199680A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700124A GB0700124D0 (en) 2007-01-04 2007-01-04 GPCR agonists
GB0708740A GB0708740D0 (en) 2007-05-08 2007-05-08 Gpcr agonists
GB0719762A GB0719762D0 (en) 2007-10-10 2007-10-10 GPCR agonists
PCT/GB2008/050011 WO2008081205A1 (en) 2007-01-04 2008-01-04 Piperidine gpcr agonists

Publications (1)

Publication Number Publication Date
IL199680A0 true IL199680A0 (en) 2010-04-15

Family

ID=39203222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199680A IL199680A0 (en) 2007-01-04 2009-07-02 Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof

Country Status (27)

Country Link
US (1) US20100022591A1 (cg-RX-API-DMAC7.html)
EP (2) EP2383270A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010514829A (cg-RX-API-DMAC7.html)
KR (1) KR20090104092A (cg-RX-API-DMAC7.html)
CN (1) CN101627036A (cg-RX-API-DMAC7.html)
AR (1) AR064736A1 (cg-RX-API-DMAC7.html)
AT (1) ATE531710T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008203673A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0806468A2 (cg-RX-API-DMAC7.html)
CA (1) CA2674093A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008000017A1 (cg-RX-API-DMAC7.html)
DK (1) DK2114931T3 (cg-RX-API-DMAC7.html)
EA (1) EA015805B9 (cg-RX-API-DMAC7.html)
ES (1) ES2376015T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110964T1 (cg-RX-API-DMAC7.html)
IL (1) IL199680A0 (cg-RX-API-DMAC7.html)
MA (1) MA31084B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009007180A (cg-RX-API-DMAC7.html)
NZ (1) NZ578144A (cg-RX-API-DMAC7.html)
PE (1) PE20081849A1 (cg-RX-API-DMAC7.html)
PL (1) PL2114931T3 (cg-RX-API-DMAC7.html)
PT (1) PT2114931E (cg-RX-API-DMAC7.html)
RS (1) RS52168B (cg-RX-API-DMAC7.html)
SA (1) SA08280756B1 (cg-RX-API-DMAC7.html)
SI (1) SI2114931T1 (cg-RX-API-DMAC7.html)
TW (1) TWI380818B (cg-RX-API-DMAC7.html)
WO (1) WO2008081205A1 (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2591922A1 (en) * 2004-12-24 2006-06-29 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
JP2008545009A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20081659A1 (es) * 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
MX2010003916A (es) 2007-10-10 2010-05-05 Novartis Ag Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
GB0812642D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
US8334288B2 (en) 2008-07-11 2012-12-18 Irm Llc 4-phenoxymethylpiperidines as modulators of GPR119 activity
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
TWI508965B (zh) 2008-12-23 2015-11-21 Boehringer Ingelheim Int 有機化合物的鹽形式
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
EA201200046A1 (ru) 2009-06-24 2012-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Новые соединения, фармацевтическая композиция и связанные с ними способы
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
ITMI20100770A1 (it) 2010-05-03 2011-11-04 Dipharma Francis Srl Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
ITMI20100984A1 (it) 2010-05-31 2011-12-01 Dipharma Francis Srl Procedimento per la preparazione di ossadiazoli
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR083904A1 (es) 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012138845A1 (en) * 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
JP2014517036A (ja) 2011-06-16 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 置換シクロプロピル化合物、そのような化合物を含有する組成物および治療方法
KR101985384B1 (ko) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9422266B2 (en) 2011-09-30 2016-08-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
JP6101279B2 (ja) 2011-11-15 2017-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｇｐｒ１１９アゴニストとして有用な置換シクロプロピル化合物
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
KR101726819B1 (ko) * 2014-10-27 2017-04-13 동아에스티 주식회사 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
BR112018072401A2 (pt) 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina
EP3421455B1 (en) * 2017-06-29 2019-03-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
DE4222565A1 (de) * 1992-07-09 1994-01-13 Hoechst Ag Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE4311967A1 (de) * 1993-04-10 1994-10-13 Hoechst Ag Smektische Flüssigkristallmischung
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705346B1 (fr) * 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
DE69422379T2 (de) 1993-08-13 2000-05-11 Zeneca Ltd., London Thiadiazolderivate und ihre verwendung als fungizide oder insektizide
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
WO1998006720A1 (fr) * 1996-08-09 1998-02-19 Eisai Co., Ltd. Derives de benzopiperidine
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
CA2344591A1 (en) 1998-09-01 2000-03-09 Basf Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
CN1206220C (zh) * 2000-11-21 2005-06-15 三菱化学株式会社 生产2－(4－吡啶基)乙硫醇的方法
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
AU2002331766A1 (en) 2001-08-31 2003-03-18 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
CN101195604A (zh) 2001-09-21 2008-06-11 索尔瓦药物有限公司 具有效cb1-拮抗活性的4,5-二氢-1h-吡唑衍生物
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
JP4313671B2 (ja) 2001-09-21 2009-08-12 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｃｂ１−拮抗活性を有する新規４，５−ジヒドロ−１ｈ−ピラゾール誘導体
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
US20040248956A1 (en) 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
EP1482794A1 (en) 2002-03-06 2004-12-08 Merck & Co., Inc. Method of treatment or prevention of obesity
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
US20050154202A1 (en) 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
CA2481313A1 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
JP4202319B2 (ja) 2002-07-29 2008-12-24 エフ．ホフマン−ラ ロシュ アーゲー 新規ベンゾジオキソール
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004034968A2 (en) 2002-08-20 2004-04-29 The Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
MXPA05004115A (es) 2002-10-18 2005-06-22 Pfizer Prod Inc Ligandos del receptor cannabionoide y usos de los mismos.
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
KR20050088194A (ko) 2002-12-19 2005-09-02 머크 앤드 캄파니 인코포레이티드 치환된 아미드
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
CA2511859A1 (en) 2003-01-02 2004-07-22 Alexander Mayweg Novel cb 1 receptor inverse agonists
CN100360527C (zh) 2003-01-02 2008-01-09 霍夫曼-拉罗奇有限公司 Cb1受体反激动剂
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
KR20050100686A (ko) 2003-02-13 2005-10-19 사노피-아벤티스 도이칠란트 게엠베하 질소-치환된헥사하이드로피라지노[1,2-ａ]피리미딘-4,7-디온 유도체,이의 제조방법 및 의약으로서의 이의 용도
MXPA05007516A (es) 2003-02-13 2006-01-27 Sanofi Aventis Deutschland Derivados de hexahidropirazino[1,2-a]pirimidina -4, 7-diona sustituidos, metodo para producirlos y su uso como medicamentos.
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
EP1606019A1 (en) 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
EP1711491A1 (en) 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
CA2591922A1 (en) * 2004-12-24 2006-06-29 Prosidion Limited G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
JP5065908B2 (ja) 2004-12-24 2012-11-07 プロシディオン・リミテッド Ｇタンパク質結合受容体作動薬
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
AU2006264651A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
JP2008545009A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
JP2009532453A (ja) * 2006-04-06 2009-09-10 プロシディオン・リミテッド ヘテロサイクリックｇｐｃｒアゴニスト
JP5330260B2 (ja) * 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション 二環式化合物ならびに抗糖尿病薬としての使用
WO2008081204A1 (en) * 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
PE20081659A1 (es) * 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
EP2114936A1 (en) * 2007-01-04 2009-11-11 Prosidion Limited Piperidine gpcr agonists

Also Published As

Publication number Publication date
ATE531710T1 (de) 2011-11-15
US20100022591A1 (en) 2010-01-28
EA200900796A1 (ru) 2010-02-26
PT2114931E (pt) 2012-01-12
BRPI0806468A2 (pt) 2011-09-27
PE20081849A1 (es) 2009-01-26
MX2009007180A (es) 2009-07-15
AU2008203673A1 (en) 2008-07-10
PL2114931T3 (pl) 2012-03-30
RS52168B (sr) 2012-08-31
DK2114931T3 (da) 2012-02-13
AR064736A1 (es) 2009-04-22
TW200835489A (en) 2008-09-01
HK1135704A1 (en) 2010-06-11
CL2008000017A1 (es) 2008-08-01
HRP20110964T1 (hr) 2012-01-31
TWI380818B (zh) 2013-01-01
CA2674093A1 (en) 2008-07-10
EP2114931B1 (en) 2011-11-02
JP2010514829A (ja) 2010-05-06
SI2114931T1 (sl) 2012-02-29
CN101627036A (zh) 2010-01-13
NZ578144A (en) 2011-03-31
EP2114931A1 (en) 2009-11-11
EA015805B1 (ru) 2011-12-30
SA08280756B1 (ar) 2011-01-24
EA015805B9 (ru) 2012-03-30
EP2383270A1 (en) 2011-11-02
ES2376015T3 (es) 2012-03-08
KR20090104092A (ko) 2009-10-05
MA31084B1 (fr) 2010-01-04
WO2008081205A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
IL199680A0 (en) Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof
EP2076604A4 (en) GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
IL230759A0 (en) Converted acyl anilide, the pharmaceutical composition containing it and its uses
IL195580A (en) L – fkbp polypeptides, preparations containing them, methods of preparation and use
IL208220A0 (en) Substituted imidazoquinolines, compositions comprising the same and uses thereof
ZA200705839B (en) Cyclohexylamides as dopamine D3, D2 and 5HT1A antagonists
ZA201001221B (en) 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
IL212836A0 (en) Azaquinolinone derivatives, compositions comprising the same and uses thereof
IL201973A0 (en) 3,3-spiroindolinone derivatives
PL2271725T3 (pl) Kompozycje zawierające 2,3,3,3-tetrafluoropropen i 1,1,1-trifluoropropen
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
IL205880A0 (en) Aminoglycoside analogs, compositions comprising the same and uses thereof
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
ZA201001797B (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
IL204211A (en) 2epha antidote, a drug containing it and its uses
IL205057A0 (en) Pyrimidyl indoline compound, composition comprising the same and uses thereof
IL190781A0 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EP2282735A4 (en) COMPOUNDS, COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
IL202038A0 (en) Rna antagonist compounds, compositions comprising the same and uses thereof
IL215050A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
GB0706077D0 (en) Methods, Compositions and uses thereof
IL215051A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
GB0601143D0 (en) Uses, methods and compositions
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni